Article

Hanmi Pharmaceutical Group will expand cash dividends to enhance shareholder value, with record earnings from affiliates. Dividends will be 300 KRW per common share of Hanmi Science (0.79% yield), 2,000 KRW for Hanmi Pharmaceutical (0.40% yield), and 650 KRW for JVM (2.5% yield), pending approval at shareholder meetings.

The company aims to return a percentage of net profit to shareholders, targeting over 30% for Hanmi Science and over 20% for the others. By 2030, Hanmi Group seeks combined sales of 5 trillion KRW, focusing on obesity, anti-aging, digital healthcare, and robotics. The strategy includes expanding high-value businesses and achieving significant operating profit margins.